Woodline Partners LP Immunovant, Inc. Transaction History

Woodline Partners LP

  • $11 Billion
  • Q3 2024

A detailed history of Woodline Partners LP transactions in Immunovant, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 1,414,977 shares of IMVT stock, worth $38.9 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
1,414,977
Previous 1,823,415 22.4%
Holding current value
$38.9 Million
Previous $48.1 Million 19.14%
% of portfolio
0.35%
Previous 0.48%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$27.51 - $27.51 $11.2 Million - $11.2 Million
-408,438 Reduced 22.4%
1,414,977 $38.9 Million
Q2 2024

Aug 14, 2024
BUY
$25.1 - $31.61 $13.4 Million - $16.9 Million
533,911 Added 41.4%
1,823,415 $48.1 Million
Q1 2024

May 15, 2024
BUY
$30.27 - $43.79 $16.3 Million - $23.6 Million
539,238 Added 71.87%
1,289,504 $41.7 Million
Q4 2023

Feb 14, 2024
SELL
$31.31 - $44.19 $6.69 Million - $9.45 Million
-213,817 Reduced 22.18%
750,266 $31.6 Million
Q3 2023

Nov 14, 2023
BUY
$18.55 - $39.96 $6.1 Million - $13.1 Million
328,992 Added 51.8%
964,083 $37 Million
Q2 2023

Aug 14, 2023
BUY
$14.2 - $23.75 $7.06 Million - $11.8 Million
497,499 Added 361.58%
635,091 $12 Million
Q1 2023

May 15, 2023
SELL
$15.27 - $19.72 $10.4 Million - $13.4 Million
-679,367 Reduced 83.16%
137,592 $2.13 Million
Q4 2022

Feb 14, 2023
SELL
$6.59 - $17.75 $6.24 Million - $16.8 Million
-947,331 Reduced 53.69%
816,959 $14.5 Million
Q3 2022

Nov 14, 2022
BUY
$3.93 - $6.37 $6.57 Million - $10.7 Million
1,672,190 Added 1815.62%
1,764,290 $9.85 Million
Q2 2022

Aug 15, 2022
BUY
$3.38 - $5.65 $311,298 - $520,365
92,100 New
92,100 $359,000
Q4 2021

Feb 14, 2022
SELL
$7.33 - $9.32 $1.77 Million - $2.25 Million
-241,599 Closed
0 $0
Q3 2021

Nov 15, 2021
SELL
$7.01 - $11.37 $24.6 Million - $39.9 Million
-3,508,976 Reduced 93.56%
241,599 $2.1 Million
Q2 2021

Aug 16, 2021
BUY
$9.4 - $16.85 $26.8 Million - $48.1 Million
2,853,958 Added 318.3%
3,750,575 $39.6 Million
Q1 2021

May 17, 2021
BUY
$13.08 - $49.6 $7.78 Million - $29.5 Million
594,714 Added 196.99%
896,617 $14.4 Million
Q4 2020

Feb 16, 2021
BUY
$36.36 - $52.71 $5.84 Million - $8.47 Million
160,733 Added 113.86%
301,903 $13.9 Million
Q3 2020

Nov 16, 2020
SELL
$22.61 - $38.9 $2.03 Million - $3.49 Million
-89,738 Reduced 38.86%
141,170 $4.97 Million
Q2 2020

Aug 14, 2020
SELL
$13.87 - $28.44 $1.31 Million - $2.68 Million
-94,275 Reduced 28.99%
230,908 $5.62 Million
Q1 2020

May 15, 2020
BUY
$8.36 - $17.13 $440,103 - $901,791
52,644 Added 19.32%
325,183 $5.06 Million
Q4 2019

Feb 14, 2020
BUY
$10.02 - $16.4 $2.73 Million - $4.47 Million
272,539 New
272,539 $4.32 Million

Others Institutions Holding IMVT

# of Institutions
211
Shares Held
66M
Call Options Held
2.3M
Put Options Held
631K
View Full List

About Immunovant, Inc.

IMVT Quotes by TradingView
  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email